My lab is focused on studying adverse cardiovascular effects of common chronic diseases (hypertension, type 2 diabetes, thromboembolic disorders) and optimizing drug therapy to minimize risks of these diseases.
A major focus is on adverse effects of chronic uncontrolled blood pressure (hypertension) and ways to optimize antihypertensive drug therapy to mitigate these adverse effects. I have particular expertise in the area of treatment-resistant hypertension.
My research spans population and clinical sciences related to cardiovascular disease and its treatment.
Retrospective database studies using:
Prospective cohort studies through PCORnet
I am also interested in research on methods for using electronic health record (EHR) data, including how to minimize misclassification when measuring longitudinal drug exposure from EHR prescribing data, and methods for dealing with missingness in EHR data and biases associated with missing data.
Current funding for the lab is through the National Heart, Lung and Blood Institute (NIH) via our work on optimizing antihypertensive drug selection; and through the Patient-Centered Outcomes Research Institute to study the relationship between antihypertensive use and COVID-19 outcomes.